KR102778218B1 - 심혈관 병태에서의 세마글루타이드 - Google Patents

심혈관 병태에서의 세마글루타이드 Download PDF

Info

Publication number
KR102778218B1
KR102778218B1 KR1020227036550A KR20227036550A KR102778218B1 KR 102778218 B1 KR102778218 B1 KR 102778218B1 KR 1020227036550 A KR1020227036550 A KR 1020227036550A KR 20227036550 A KR20227036550 A KR 20227036550A KR 102778218 B1 KR102778218 B1 KR 102778218B1
Authority
KR
South Korea
Prior art keywords
semaglutide
pharmaceutical composition
mace
subject
fatal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227036550A
Other languages
English (en)
Korean (ko)
Other versions
KR20220147712A (ko
Inventor
올루프 크리스티안 호이베르그 한센
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58668875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102778218(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Priority to KR1020257007151A priority Critical patent/KR20250038818A/ko
Publication of KR20220147712A publication Critical patent/KR20220147712A/ko
Application granted granted Critical
Publication of KR102778218B1 publication Critical patent/KR102778218B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
KR1020227036550A 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드 Active KR102778218B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257007151A KR20250038818A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP16167458.5 2016-04-28
EP16167458 2016-04-28
EP16188262.6 2016-09-12
EP16188262 2016-09-12
PCT/EP2017/060160 WO2017186896A1 (en) 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions
KR1020187033310A KR20180135012A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187033310A Division KR20180135012A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257007151A Division KR20250038818A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드

Publications (2)

Publication Number Publication Date
KR20220147712A KR20220147712A (ko) 2022-11-03
KR102778218B1 true KR102778218B1 (ko) 2025-03-10

Family

ID=58668875

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227036550A Active KR102778218B1 (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드
KR1020257007151A Pending KR20250038818A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드
KR1020187033310A Ceased KR20180135012A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257007151A Pending KR20250038818A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드
KR1020187033310A Ceased KR20180135012A (ko) 2016-04-28 2017-04-28 심혈관 병태에서의 세마글루타이드

Country Status (24)

Country Link
US (3) US12569543B2 (enExample)
EP (1) EP3448416B1 (enExample)
JP (1) JP7221694B2 (enExample)
KR (3) KR102778218B1 (enExample)
CN (1) CN109069589B (enExample)
AU (2) AU2017256774B2 (enExample)
BR (1) BR112018072020A2 (enExample)
CA (1) CA3022535A1 (enExample)
CL (1) CL2018003045A1 (enExample)
DK (1) DK3448416T3 (enExample)
ES (1) ES2928007T3 (enExample)
HR (1) HRP20221150T1 (enExample)
HU (1) HUE060040T2 (enExample)
IL (1) IL262390B1 (enExample)
MA (1) MA44762A (enExample)
MX (1) MX2018012700A (enExample)
MY (1) MY202967A (enExample)
PH (1) PH12018502274B1 (enExample)
PL (1) PL3448416T3 (enExample)
RS (1) RS63630B1 (enExample)
RU (1) RU2768283C2 (enExample)
SI (1) SI3448416T1 (enExample)
WO (1) WO2017186896A1 (enExample)
ZA (2) ZA202507395B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3448416T3 (pl) 2016-04-28 2022-11-07 Novo Nordisk A/S Semaglutyd w schorzeniach sercowo-naczyniowych
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
MY206306A (en) * 2018-10-26 2024-12-07 Novo Nordisk As Stable semaglutide compositions and uses thereof
CN113194929B (zh) * 2018-12-21 2022-12-09 诺和诺德股份有限公司 Glp-1肽的喷雾干燥工艺
IL294521A (en) * 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
CN114699510B (zh) * 2021-12-29 2024-07-16 浙江湃肽生物有限公司 一种司美格鲁肽微针阵列及其制备方法
AU2023285400A1 (en) * 2022-06-08 2024-12-05 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
CN117462654A (zh) * 2023-09-28 2024-01-30 武汉大学人民医院（湖北省人民医院） 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用
US20260199436A1 (en) * 2025-01-16 2026-07-16 Novo Nordisk A/S Semaglutide in medical therapy including weight management

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015071355A1 (en) * 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2298378T3 (es) * 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
EP1494704A1 (en) * 2002-04-04 2005-01-12 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
KR101243648B1 (ko) 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN107028924A (zh) 2009-10-02 2017-08-11 勃林格殷格翰国际有限公司 包含bi‑1356和二甲双胍的药物组合物
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX341025B (es) * 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
MX377589B (es) * 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP6126097B2 (ja) 2011-09-06 2017-05-10 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
EP2854812A1 (en) 2012-05-24 2015-04-08 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
US20150290294A1 (en) 2012-11-02 2015-10-15 Mansoor Husain Methods for inhibiting platelet aggregation using glp-1 receptor agonists
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
JP2016510795A (ja) 2013-03-15 2016-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
CN107613986A (zh) 2015-04-07 2018-01-19 英特塞普特医药品公司 用于组合疗法的药物组合物
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
PL3448416T3 (pl) * 2016-04-28 2022-11-07 Novo Nordisk A/S Semaglutyd w schorzeniach sercowo-naczyniowych

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015071355A1 (en) * 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof

Also Published As

Publication number Publication date
IL262390A (en) 2018-12-31
EP3448416B1 (en) 2022-08-10
JP2019514925A (ja) 2019-06-06
RS63630B1 (sr) 2022-10-31
US20190134162A1 (en) 2019-05-09
AU2017256774B2 (en) 2024-07-11
KR20250038818A (ko) 2025-03-19
CA3022535A1 (en) 2017-11-02
CL2018003045A1 (es) 2018-12-14
MY202967A (en) 2024-05-31
KR20220147712A (ko) 2022-11-03
RU2768283C2 (ru) 2022-03-23
US12569543B2 (en) 2026-03-10
ZA202507394B (en) 2025-09-25
PL3448416T3 (pl) 2022-11-07
HRP20221150T1 (hr) 2022-11-25
RU2018140900A3 (enExample) 2020-09-28
CN109069589B (zh) 2022-09-06
RU2018140900A (ru) 2020-05-28
PH12018502274A1 (en) 2019-09-09
KR20180135012A (ko) 2018-12-19
MX2018012700A (es) 2019-01-30
MA44762A (fr) 2019-03-06
AU2024227113A1 (en) 2024-10-31
US20250262281A1 (en) 2025-08-21
JP7221694B2 (ja) 2023-02-14
ES2928007T3 (es) 2022-11-14
CN109069589A (zh) 2018-12-21
PH12018502274B1 (en) 2024-02-28
ZA202507395B (en) 2025-09-25
DK3448416T3 (da) 2022-10-03
HUE060040T2 (hu) 2023-01-28
SI3448416T1 (sl) 2022-10-28
US20250288649A1 (en) 2025-09-18
AU2017256774A1 (en) 2018-11-01
EP3448416A1 (en) 2019-03-06
IL262390B1 (en) 2023-05-01
WO2017186896A1 (en) 2017-11-02
BR112018072020A2 (pt) 2019-02-12

Similar Documents

Publication Publication Date Title
US20250262281A1 (en) Semaglutide in Cardiovascular Conditions
AU2024201937A1 (en) Liraglutide in cardiovascular conditions
CN110022935A (zh) 用于心血管病况的德谷胰岛素
US20200181222A1 (en) Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications
HK1261741B (en) Semaglutide in cardiovascular conditions
HK1261741A1 (en) Semaglutide in cardiovascular conditions
US20190091295A1 (en) Liraglutide in Renal Conditions
WO2017149109A1 (en) Liraglutide in diabetic foot ulcer
BR122025010585A2 (pt) Uso de semaglutida para reduzir o risco de um evento cardiovascular adverso maior (mace) em indivíduos com diabetes mellitus tipo 2 e alto risco cardiovascular
HK1259166B (en) Liraglutide in cardiovascular conditions
HK1259166A1 (en) Liraglutide in cardiovascular conditions
EP1525888A1 (en) Angiogenically effective unit dose of FGF-2 and method of use

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601